Neonatal screening for cystic fibrosis

BMJ 1998; 316 doi: 10.1136/bmj.316.7129.404 (Published 7 February 1998)
Cite this as: BMJ 1998;316:404

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

No evidence yet of any benefit

  1. Nicholas J Wald, Professora,
  2. Joan K Morris, Senior lecturera
  1. a Wolfson Institute of Preventive Medicine, St Bartholomew's and the Royal London School of Medicine and Dentistry, London EC1M 6BQ

    Neonatal screening for cystic fibrosis by using a simple test that can be performed on the “blood spots” routinely collected in screening for phenylketonuria and hypothyroidism raises exciting possibilities. The test is relatively easy to perform and the specimen is already collected, but even a simple test performed on millions of individuals will be costly, and the early knowledge of a serious disorder will cause more harm than good if there is no effective remedy. The results of a large randomised trial of neonatal screening for cystic fibrosis have recently been published in the New England Journal of Medicine.1 The trial involved two thirds of a million newborn infants and their subsequent follow up. The conclusion that screening and subsequent treatment improves the growth and development of children with cystic fibrosis was met with enthusiasm.2 Unfortunately the conclusion may not …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL